Guardant Health, Inc. Q2 2026 Earnings Call Summary
Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.
How this was made
The 30-second read
Why it matters
Key new trading inputs are the raised 2026 revenue guidance, the plan for ADLT designation to lift Medicare reimbursement, UnitedHealth coverage starting Aug 1, and the updated free cash flow burn range driven by screening lab capex.
Market read
Traders can reprice Guardant Health on raised revenue guidance and near-term reimbursement catalysts, while monitoring cash burn and regulatory dependencies that could delay monetization.
What to watch
ASP improvements are described as delayed due to historical accrual/collection timing, so near-term revenue quality and margin timing could disappoint even if volumes grow.
Background
The piece summarizes Guardant Health’s Q2 2026 earnings call, focusing on growth drivers, reimbursement and FDA milestones, and updated financial outlook.
Ticker impact
Guardant Health raised full-year 2026 revenue guidance to $1.34B-$1.36B and reiterated cash-flow breakeven by end-2027 on earnings-call updates.
Bias upward with volatility around reimbursement timing and the higher 2026 free-cash-flow burn.
The article discloses multiple forward-looking catalysts (FDA approval of Guardant360 Liquid CDx, UnitedHealth coverage effective Aug 1, ADLT designation plan) alongside a quantified downside (FCF burn guidance $195M-$205M) that can drive both upside and risk repricing.
Market effects
Reimbursement expansion for liquid biopsy tests and Medicare/ADLT pathway expectations may improve read-through sentiment for precision oncology diagnostics.
US-focused coverage and Medicare reimbursement updates can shift demand expectations for US payers and providers.
Limited direct global impact in the text, but FDA and reimbursement mechanics can influence international investor sentiment toward US CDx platforms.
Counterpoint
The guidance optimism may be tempered by the quantified increase in full-year free cash flow burn and by regulatory dependency for ESR1 monitoring tied to FDA approval of camizestrant.
Key entities
- companyGuardant Health, Inc.
Subject of the earnings call summary, providing updated guidance, reimbursement plans, and operational efficiency details.
- companyUnitedHealth Group
Announced coverage for Shield effective Aug 1, 2026, described as the first major insurer to cover ahead of USPSTF updates.
- regulatorFDA
Approved Guardant360 Liquid CDx and is a dependency for ESR1 monitoring contingent on approval of camizestrant.
- organizationAmerican Cancer Society (ACS)
Guidelines inclusion for Shield triggers state-level coverage mandates in about a dozen states.
- regulatorUSPSTF
Updates are referenced as a timing catalyst for broader coverage, with Shield coverage already starting via UnitedHealth.
